Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 12/20 | 0.72 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8305231 | 0.89 | ALOX5 (0.58) | ALOX5EPHX2SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL5986472 | 0.88 | ALOX5 (0.56) | ALOX5EPHX2MEN1KMT2AABL1 | |
| SCHEMBL9026054 | 0.87 | ALOX5 (0.55) | ALOX5EPHX2SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL9026098 | 0.86 | ALOX5 (0.55) | ALOX5EPHX2KDM4EMEN1ALDH1A1 | |
| SCHEMBL9025912 | 0.85 | ALOX5 (0.54) | ALOX5EPHX2LMNA | |
| SCHEMBL9025672 | 0.85 | ALOX5 (0.53) | ALOX5EPHX2 | |
| SCHEMBL8309551 | 0.84 | ALOX5 (1.00) | ALOX5EPHX2SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL9282958 | 0.82 | ALOX5 (0.59) | ALOX5EPHX2SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL9025000 | 0.82 | ALOX5 (0.56) | ALOX5EPHX2 | |
| SCHEMBL9024981 | 0.82 | ALOX5 (0.50) | ALOX5HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1998058645-A1 | (S)-(-)-N-[3- [5-[(4-FLUOROPHENYL)METHYL] -2-THIENYL]-1-METHYL -2-PROPYNYL]-N-HYDROXYUREA | SEPRACOR, INC. (US) | 1998-12-30 | — | — | WO | claimed |
| EP-0804157-A1 | AEROSOL DRUG FORMULATIONS CONTAINING VITAMIN E | Abbott Laboratories (US) | 1997-11-05 | — | — | EP | claimed |
| EP-0667855-A4 | SUBSTITUTED ARYLALKYNYL- AND HETEROARYLALKYNYL-N-HYDROXYUREA INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS. | ABBOTT LAB (US) | 1996-02-21 | — | — | EP | claimed |
| WO-1995024892-A1 | AEROSOL DRUG FORMULATIONS CONTAINING VITAMIN E | ABBOTT LABORATORIES (US) | 1995-09-21 | — | — | WO | claimed |
| EP-0667855-A1 | SUBSTITUTED ARYLALKYNYL- AND HETEROARYLALKYNYL-N-HYDROXYUREA INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | ABBOTT LABORATORIES (US) | 1995-08-23 | — | — | EP | claimed |
| WO-1994011342-A1 | SUBSTITUTED ARYLALKYNYL- AND HETEROARYLALKYNYL-N-HYDROXYUREA INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | ABBOTT LABORATORIES (US) | 1994-05-26 | — | — | WO | claimed |
| EP-2598141-A2 | PHENYLALKYL N-HYDROXYUREAS FOR TREATING LEUKOTRIENE RELATED PATHOLOGIES | Tallikut Pharmaceuticals, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012015750-A2 | PHENYLALKYL N-HYDROXYUREAS FOR TREATING LEUKOTRIENE RELATED PATHOLOGIES | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
| EP-1871908-A2 | SUSCEPTIBILITY GENE FOR MYOCARDIAL INFARCTION, STROKE AND PAOD; METHODS OF TREATMENT | Decode Genetics EHF. (IS) | 2008-01-02 | — | — | EP | disclosed |
| EP-1718284-A2 | SUSCEPTIBILITY GENE FOR MYOCARDIAL INFRACTION, STROKE, AND PAOD; METHODS OF TREATMENT | Decode Genetics EHF. (IS) | 2006-11-08 | — | — | EP | disclosed |
| WO-2006105439-A2 | SUSCEPTIBILITY GENE FOR MYOCARDIAL INFARCTION, STROKE. AND PAOD; METHODS OF TREATMENT | DECODE GENETICS EHF. (IS) | 2006-10-05 | — | — | WO | disclosed |
| EP-1579010-A2 | SUSCEPTIBILITY GENE FOR MYOCARDIAL INFARCTION; METHODS OF TREATMENT | Decode Genetics EHF. (IS) | 2005-09-28 | — | — | EP | disclosed |
| WO-2005075022-A2 | SUSCEPTIBILITY GENE FOR MYOCARDIAL INFRACTION, STROKE, AND PAOD; METHODS OF TREATMENT | DECODE GENETICS EHF. (IS) | 2005-08-18 | — | — | WO | disclosed |
| WO-1998042383-A1 | CHARGED LIPIDS AND USES FOR THE SAME | IMARX PHARMACEUTICAL CORP. (US) | 1998-10-01 | — | — | WO | disclosed |
| EP-0804157-A1 | AEROSOL DRUG FORMULATIONS CONTAINING VITAMIN E | Abbott Laboratories (US) | 1997-11-05 | — | — | EP | disclosed |
| EP-0667855-A4 | SUBSTITUTED ARYLALKYNYL- AND HETEROARYLALKYNYL-N-HYDROXYUREA INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS. | ABBOTT LAB (US) | 1996-02-21 | — | — | EP | disclosed |
| WO-1995030671-A1 | SUBSTITUTED ARYL- AND HETEROARYLALKENYL-N-HYDROXYUREA INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | ABBOTT LABORATORIES (US) | 1995-11-16 | — | — | WO | disclosed |
| WO-1995024892-A1 | AEROSOL DRUG FORMULATIONS CONTAINING VITAMIN E | ABBOTT LABORATORIES (US) | 1995-09-21 | — | — | WO | disclosed |
| EP-0667855-A1 | SUBSTITUTED ARYLALKYNYL- AND HETEROARYLALKYNYL-N-HYDROXYUREA INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | ABBOTT LABORATORIES (US) | 1995-08-23 | — | — | EP | disclosed |
| WO-1994011342-A1 | SUBSTITUTED ARYLALKYNYL- AND HETEROARYLALKYNYL-N-HYDROXYUREA INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | ABBOTT LABORATORIES (US) | 1994-05-26 | — | — | WO | disclosed |